X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

Are Indian Pharmaceutical Companies Up For The Chinese Challenge?

Content Team by Content Team
10th November 2020
in News
Are Indian Pharmaceutical Companies Up For The Chinese Challenge?

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

For long Asian Countries, specifically China and India has been known to supply the world with pharmaceuticals at a very reasonable price. With that being said, immediately our focus turns to the quality of research & development as well as the raw materials used for producing effective formulations.

With all the positive vibes coming from India, it has been lately observed that China too has actively increased the exports of its active pharmaceutical ingredients. What Indian pharmaceutical companies have done is that they have turned this trend of China’s upward API swing as an opportunity for themselves by using their ingredients to supply medicines at a relatively lesser price by lowering the production cost as well as the R & D spend.

China, on the other hand has also been expanding when it comes to formulations. China’s global share of formulations exports grew from 0.4% in 2009 to 1.2% in 2018 whereas India’s grew from 1.5% to 3.6% during the same tenure. EU & North America is dominated by Chinese formulations which stand at 36% despite the fact that the rules & regulations in those regions are more stringent. This figure was hardly 19% in 2009. It shows how much work has been done both on the R & D as well as on the analytics front by Chinese companies in order to penetrate into this huge market.

The rising share of Chinese formulations is due to the high and improved standards that have been set up by manufacturers. Breaking the adverse apprehension of buyers across regions has played a pivotal role in ensuring that the share keeps rising at a brisk pace.  Artificial Intelligence used by the Chinese manufacturers has also played its part in uplifting the quality quotient in the formulations by a decent margin. Wealthy countries too are making it tough for India by protecting their industries to ensure drug security. Steps taken by the US to eliminate drug imports both as API & Formulations are a move towards this direction. If this order is strictly taken into consideration, Indian Pharma shall be heavily affected. The fact is that for Indian Pharma giants, the US is a very critical market in order to maintain their high-profit margins.

The outbreak of COVID- 19 has however improved India’s perssspective and possibilities of again emerging as a key pharmaceutical player as far as lower costs and quality product is concerned. The lowest quoted price for a COVID vaccine comes from India and without a shred of doubt will benefit low & middle-income countries.

Although India’s contribution to the world of pharmaceuticals has been unmatched yet the Government has never used it as a tool to impose its foreign policy. Can’t say this in the case of China though, as the country has always tried to leverage on its Pharmaceutical prowess in making agreements and contracts with other countries.

Previous Post

The Falling Graph of Dose Contract Manufacturing

Next Post

NHS Digital deals to improve data sharing between organizations.

Related Posts

WuXi Biologics and Virogen Bio partner to advance VG712
News

WuXi Biologics and Virogen Bio partner to advance VG712

19th June 2025
Construction of WuXi Biologics Microbial Manufacturing Site
News

Construction of WuXi Biologics Microbial Manufacturing Site

19th June 2025
Beyfortus From Sanofi to Make Imprint in 2025 26 RSV Season
News

Beyfortus From Sanofi to Make Imprint in 2025-26 RSV Season

19th June 2025
Thermo-Fischer-Accelerator Drug Development an Ideal Choice
News

Thermo Fischer Accelerator Drug Development an Ideal Choice

19th June 2025
IQVIA Custom Built AI Agents for Life Sciences Healthcare
News

IQVIA Custom-Built AI Agents for Life Sciences, Healthcare

19th June 2025
SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Next Post
NHS Digital deals to improve data sharing between organizations.

NHS Digital deals to improve data sharing between organizations.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In